These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21310819)

  • 1. IL-1β receptor antagonist reduces inflammation in hemodialysis patients.
    Hung AM; Ellis CD; Shintani A; Booker C; Ikizler TA
    J Am Soc Nephrol; 2011 Mar; 22(3):437-42. PubMed ID: 21310819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients.
    Hung AM; Limkunakul C; Placido JS; Siew ED; Ellis CD; Shintani A; Ikizler TA
    J Nephrol; 2014 Dec; 27(6):681-8. PubMed ID: 24609887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled pilot trial of anakinra for hemodialysis inflammation.
    Dember LM; Hung A; Mehrotra R; Hsu JY; Raj DS; Charytan DM; Mc Causland FR; Regunathan-Shenk R; Landis JR; Kimmel PL; Kliger AS; Himmelfarb J; Ikizler TA;
    Kidney Int; 2022 Nov; 102(5):1178-1187. PubMed ID: 35863559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study.
    Galea J; Ogungbenro K; Hulme S; Patel H; Scarth S; Hoadley M; Illingworth K; McMahon CJ; Tzerakis N; King AT; Vail A; Hopkins SJ; Rothwell N; Tyrrell P
    J Neurosurg; 2018 Feb; 128(2):515-523. PubMed ID: 28298024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.
    Morton AC; Rothman AM; Greenwood JP; Gunn J; Chase A; Clarke B; Hall AS; Fox K; Foley C; Banya W; Wang D; Flather MD; Crossman DC
    Eur Heart J; 2015 Feb; 36(6):377-84. PubMed ID: 25079365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the Rectus Sheath Block Analgesia Reduce the Inflammatory Response Biomarkers' IL-1ra, IL-6, IL-8, IL-10 and IL-1β Concentrations Following Surgery? A Randomized Clinical Trial of Patients with Cancer and Benign Disease.
    Purdy M; Kokki M; Anttila M; Aspinen S; Juvonen P; Korhonen R; Selander T; Kokki H; Eskelinen M
    Anticancer Res; 2016 Jun; 36(6):3005-11. PubMed ID: 27272818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial.
    Smith CJ; Hulme S; Vail A; Heal C; Parry-Jones AR; Scarth S; Hopkins K; Hoadley M; Allan SM; Rothwell NJ; Hopkins SJ; Tyrrell PJ
    Stroke; 2018 May; 49(5):1210-1216. PubMed ID: 29567761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot randomized crossover trial assessing the safety and short-term effects of pomegranate supplementation in hemodialysis patients.
    Rivara MB; Mehrotra R; Linke L; Ruzinski J; Ikizler TA; Himmelfarb J
    J Ren Nutr; 2015 Jan; 25(1):40-9. PubMed ID: 25218876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
    Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled pilot trial of anakinra and pioglitazone for protein metabolism in patients on maintenance haemodialysis.
    Ertuglu LA; Deger SM; Alsouqi A; Hung A; Gamboa J; Mambungu C; Sha F; Siew E; Abumrad NN; Ikizler TA
    J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):401-411. PubMed ID: 38178557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation.
    Rambod M; Kovesdy CP; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1691-701. PubMed ID: 18922994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of shenmai injection on patients suffering from malnutrition-inflammation complex syndrome during the maintenance hemodialysis].
    Zhang W; Tao XJ; Cheng J
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Aug; 29(8):703-6. PubMed ID: 19848201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 receptor antagonist ameliorates the pain hypersensitivity, spinal inflammation and oxidative stress induced by systemic lipopolysaccharide in neonatal rats.
    Hsieh CT; Lee YJ; Lee JW; Lu S; Tucci MA; Dai X; Ojeda NB; Lee HJ; Fan LW; Tien LT
    Neurochem Int; 2020 May; 135():104686. PubMed ID: 31987865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis.
    Olofsson PS; Sheikine Y; Jatta K; Ghaderi M; Samnegård A; Eriksson P; Sirsjö A
    Circ J; 2009 Aug; 73(8):1531-6. PubMed ID: 19574724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
    Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein.
    Hartmann G; Tschöp M; Fischer R; Bidlingmaier C; Riepl R; Tschöp K; Hautmann H; Endres S; Toepfer M
    Cytokine; 2000 Mar; 12(3):246-52. PubMed ID: 10704252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
    Fisher CJ; Dhainaut JF; Opal SM; Pribble JP; Balk RA; Slotman GJ; Iberti TJ; Rackow EC; Shapiro MJ; Greenman RL
    JAMA; 1994 Jun; 271(23):1836-43. PubMed ID: 8196140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.
    Campion GV; Lebsack ME; Lookabaugh J; Gordon G; Catalano M
    Arthritis Rheum; 1996 Jul; 39(7):1092-101. PubMed ID: 8670316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the hemodialysis membrane on the inflammatory reaction in vivo.
    Schindler R; Boenisch O; Fischer C; Frei U
    Clin Nephrol; 2000 Jun; 53(6):452-9. PubMed ID: 10879665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
    Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.